Advertisement

Short rare minisatellite variant of BORIS-MS2 is related to bladder cancer susceptibility

  • Tae Nam Kim
  • Won-Tae Kim
  • Mi-So Jeong
  • Mi-Hye Mun
  • Min-Hye Kim
  • Jeong Zoo Lee
  • Sun-Hee LeemEmail author
Research Article

Abstract

Background

BORIS/CTCFL, a paralog of CTCF and member of the cancer-testicular antigen family, is abnormally activated in multiple cancers.

Objective

We investigated the relationship between polymorphic variants of the BORIS minisatellite 2 (BORIS-MS2), located within the 5′ upstream promoter region of BORIS, and bladder cancer.

Methods

We used case-control study with 516 controls and 113 bladder cancer patients. To evaluate whether minisatellite variants play a role in BORIS expression, we examined the transcript levels of a reporter gene linked to these minisatellites in cell lines. We also examined BORIS expression in cancerous and non-cancerous bladder tissue.

Results

A statistically significant association was identified between the short rare allele (13-repeat) and bladder cancer incidence (odds ratio (OR) 2.97, 95% confidence interval (CI) [1.14, 7.74]; P = 0.020). In particular, short rare alleles in the younger group (aged < 65) were associated with statistically significant increase in bladder cancer risk (OR 5.38, CI [1.32, 21.87]; P = 0.01). The BORIS-MS2 region acted as a negative regulator, and the expression level of the luciferase reporter in bladder cancer cells was less effectively inhibited than in normal cells. Furthermore, the expression of BORIS mRNA significantly differed (P < 0.05) between normal and cancerous muscle-invasive bladder cancer tissues, and relationship to clinical parameters was observed.

Conclusions

The short rare allele of BORIS-MS2 could be used to identify bladder cancer risk. BORIS expression levels have been shown to increase with the progression of bladder cancer, could be used as a biomarker for its progression.

Keywords

CTCFL/BORIS Bladder cancer Minisatellite polymorphisms Case-control study 

Notes

Acknowledgements

We gratefully acknowledge patients and their caregivers for their willing participation in this project and for consenting to the use of information obtained from the study.

Funding

This work was supported by Alvogen (1). We declare no role of the funding body in the design of the study, the collection, analysis and interpretation of data, nor in writing the manuscript.

Compliance with ethical standards

Conflict of interest

Tae Nam Kim, Won-Tae Kim, Mi-So Jeong, Mi-Hye Mun, Min-Hye Kim, Jeong Zoo Lee and Sun-Hee Leem declare that they have no competing interest.

Ethical approval

This study was conducted with informed written consent from participants and after approval by the bioethics committees of Pusan National University Hospital (#IRB-H-1706-002-007; #IRB-H-1804-002-065 Busan, Korea) and Chungbuk National University Hospital (#IRB-2006-1; Cheongju, Korea).

References

  1. D’Arcy V, Pore N, Docquier F, Abdullaev ZK, Chernukhin I, Kita GX, Rai S, Smart M, Farrar D, Pack S et al (2008) BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours. Br J cancer 98:571–579CrossRefGoogle Scholar
  2. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC (2011) Association between smoking and risk of bladder cancer among men and women. JAMA 306:737–745CrossRefGoogle Scholar
  3. Hoffmann MJ, Muller M, Engers R, Schulz WA (2006) Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies. Biochem Pharmacol 72:1577–1588CrossRefGoogle Scholar
  4. Hong JA, Kang Y, Abdullaev Z, Flanaqan PT, Pack SD, Fischette MR, Adnani MT, Loukinov DI, Vatolin S, Risinger JI et al (2005) Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res 65:7763–7774CrossRefGoogle Scholar
  5. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90CrossRefGoogle Scholar
  6. Jeong YH, Kim MC, Ahn EK, Seol SY, Do EJ, Choi HJ, Chu IS, Kim WJ, Kim WJ, Sunwoo Y et al (2007) Rare exonic minisatellite alleles in MUC2 influence susceptibility to gastric carcinoma. PLoS ONE 2:e1163CrossRefGoogle Scholar
  7. Kaufman DS, Shipley WU, Feldman AS (2009) Bladder cancer. Lancet 374:239–249CrossRefGoogle Scholar
  8. Kwon JA, Lee SY, Ahn EK, Seol SY, Kim MC, Kim SJ, Kim SI, Chu IS, Leem SH (2010) Short rare MUC6 minisatellites-5 alleles influence susceptibility to gastric carcinoma by regulating gene. Hum Mutat 31:942–949CrossRefGoogle Scholar
  9. Lee JS, Leem SH, Lee SY, Kim SC, Park ES, Kim SB, Kim SK, Kim YJ, Kim WJ, Chu IS (2010) Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol 28:2660–2667CrossRefGoogle Scholar
  10. Loukinov DI, Pugacheva E, Vatolin S, Pack SD, Moon H, Chernukhin I, Mannan P, Larsson E, Kanduri C, Vostrov AA et al (2002) BORIS, a novel male germ-line-specific protein asssociated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprining marks in the soma. Proc Natl Acad Sci USA 99:6806–6811CrossRefGoogle Scholar
  11. Martin-Kleiner I (2012) BORIS in human cancers—a review. Eur J Cancer 48:929–935CrossRefGoogle Scholar
  12. Nakamura Y, Koyama K, Matsuchima M (1998) VNTR (variable number of tandem repeat) sequences as transcriptional, translational, or functional regulators. J Hum Genet 43:149–152CrossRefGoogle Scholar
  13. Risinger JI, Chandramouli GV, Maxwell GL, Custer M, Pack S, Loukinov D, Aprelikova O, Litzi T, Schrump DS, Murphy SK et al (2007) Global espression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression. Clin Cancer Res 13:1713–1719CrossRefGoogle Scholar
  14. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30CrossRefGoogle Scholar
  15. Vatolin S, Abdullaev Z, Pack SD, Flanagan PT, Custer M, Loukinov DI, Pugacheva E, Hong JA, Morse H 3rd, Schrump DS et al (2005) Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-AI and reactivation of other cancer-testis genes. Cancer Res 65:7751–7762CrossRefGoogle Scholar
  16. Xiao F, Pu J, Wen Q, Huang Q, Zhang Q, Huang B, Huang S, Lan A, Zhang Y, Li J et al (2017) Association between the ERCC2 Asp312Asn polymorphism and risk of cancer. Oncotarget 8:48488–48506PubMedPubMedCentralGoogle Scholar
  17. Yoon SL, Jung SI, Do EJ, Lee SR, Lee SY, Chu IS, Kim WJ, Jung J, Kim CS, Cheon SH et al (2010a) Short rare hTERT-VNTR2-2nd alleles are associated with prostate cancer susceptibility and influence gene expression. BMC Cancer 10:393CrossRefGoogle Scholar
  18. Yoon SL, Kim DC, Cho SH, Lee SY, Chu IS, Heo J, Leem SH (2010b) Susceptibility for breast cancer in young patients with short rare minisatellite alleles of BORIS. BMB Rep 43:698–703CrossRefGoogle Scholar
  19. Yoon SL, Jung SI, Kim WJ, Kim SI, Park IH, Leem SH (2011a) Variants of BORIS minisatellites and relation to prognosis of prostate cancer. Genes Genomics 33:49–56CrossRefGoogle Scholar
  20. Yoon SL, Roh YG, Lee SH, Kim SH, Kim MC, Kim SJ, Leem SH (2011b) Analysis of promoter methylation and polymorphic minisatellites of BORIS and lack of association with gastric cancer. DNA Cell Biol 30:691–698CrossRefGoogle Scholar
  21. Yoon SL, Roh YG, Chu IS, Heo JH, Kim SI, Chang H, Kang TH, Chung JW, Koh SS, Larionov V et al (2016) A polymorphic minisatellite region of BORIS regulates gene expression and its rare variants correlate with lung cancer susceptibility. Exp Mol Med 48:e246CrossRefGoogle Scholar

Copyright information

© The Genetics Society of Korea and Springer Nature B.V. 2018

Authors and Affiliations

  1. 1.Department of Urology, Medical Research InstitutePusan National University HospitalBusanSouth Korea
  2. 2.Department of Biological SciencesDong-A UniversityBusanSouth Korea

Personalised recommendations